Factor V Leiden (F5 L ) is a common genetic risk factor for venous thromboembolism in humans. We conducted a sensitized ENU mutagenesis screen for dominant thrombosuppressor genes based on perinatal lethal thrombosis in mice homozygous for Venous thromboembolism (VTE) is a common disease characterized by the formation of abnormal blood clots. Inheritance of specific genetic variants, such as the Factor V Leiden polymorphism, increases VTE susceptibility. However, only ~10% of people inheriting Factor V Leiden will develop VTE, suggesting the involvement of other genes that are currently unknown. By inducing random genetic mutations into mice with a genetic predisposition to VTE, we identified two genomic regions that reduce VTE susceptibility. The first includes the tissue factor gene and its role was confirmed by analyzing mice with an independent tissue factor gene mutation. The second contains a mutation in the Actr2 gene. These findings identify critical genes for the regulation of blood clotting risk.
Abstract
Factor V Leiden (F5 L ) is a common genetic risk factor for venous thromboembolism in humans. We conducted a sensitized ENU mutagenesis screen for dominant thrombosuppressor genes based on perinatal lethal thrombosis in mice homozygous for F5 L and also suggest a novel role for Actr2 in this process.
Introduction
Venous thromboembolism (VTE) is a common disease that affects 1 to 3 per 1000 individuals per year (1) . VTE susceptibility exhibits a complex etiology involving contributions of both genes and environment. Genetic risk factors explain approximately 60% of the overall risk for VTE (2) . Recent large-scale genome-wide association studies (GWAS) confirm ABO, F2 F5, F11, FGG and PROCR as thrombosis susceptibility genes, with only two additional novel loci, TSPAN15 and SLC44A2 identified (3) (4) (5) , leaving the major component of VTE genetic risk still unexplained.
The Factor V Leiden variant (F5 L ) is a common inherited risk factor for VTE with an average allele frequency of 3.5% in the European population (6) (7) (8) . F5 L is estimated to account for up to 25% of the genetically-attributable thrombosis risk in these populations (6) . However, penetrance is incomplete, with only ~10% of F5 L heterozygotes developing thrombosis in their lifetimes. The severity of thrombosis also varies widely among affected individuals (7, 9) , limiting the clinical utility of F5 L genotyping in the management of VTE (10) .
The incomplete penetrance and variable expressivity of thrombosis among F5 L patients can at least partially be explained by genetic interactions between F5 L and other known thrombotic risk factors such as hemizygosity for antithrombin III or proteins C or S, as well as the common prothrombin 20210 polymorphism (9, 11, 12) . However, <2% of F5 L heterozygotes would be expected to co-inherit a mutation at one or more of these loci, suggesting that a large number of additional genetic risk factors for VTE and/or modifiers of F5 L remain to be identified (3, 9) .
Mice carrying the orthologous F5 L mutation exhibit a mild to moderate prothrombotic phenotype closely mimicking the human disorder (13) . We previously reported a synthetic lethal interaction between F5 L homozygosity (F5 L/L ) and hemizygosity for tissue factor pathway inhibitor (Tfpi +/-) (14) . Nearly all mice with this lethal genotype combination (F5 L/L Tfpi +/-) succumb to widespread, systemic thrombosis in the immediate perinatal period (14) .
ENU mutagenesis in mice has been used effectively to identify novel genes involved in a number of biological processes (15, 16) . ENU-induced germline mutations transmitted from a mutagenized male mouse (G0) occur at ~1.5 mutations per megabase, at least 50 fold higher than the endogenous background mutation rate (17) . Several previous reports have successfully applied an existing phenotype as a sensitizer to identify modifier genes. A dominant suppressor screen in MecP2 deficient mice (Rett syndrome) identified a mutation in squalene epoxidase (Sqle) as a heritable suppressor, resulting in prolonged survival and amelioration of neurologic manifestations (18) . Other successful sensitized screens include analysis of mouse mutants predisposed to diabetic nephropathy (19) , a screen in Sox10 haploinsufficent mice identifying the Gli3 gene as a modifier of neurochristopathy (20) and identification of a mutation in the c-Myb gene as a dominant modifier for platelet count in Mpl deficient mice (congenital thrombocytopenia) (21) . We now report the results of a dominant, sensitized ENU mutagenesis screen for suppressors of F5 L/L Tfpi +/-dependent lethal thrombosis. (Table S3 ). Sanger sequencing analysis of the full set of F3 exons and introns, as well as 5kb upstream of exon 1, also failed to identify an ENU-induced mutation. In addition, analysis of F3 mRNA levels in liver, lung and brain tissues of adult mice failed to identify any differences in the level of expression from the ENU-mutant compared to the wildtype allele (Fig. S1 ). of the captured region covered with at least 6 independent reads (Table S4) . A total of 125 heterozygous variants were identified as candidate suppressor mutations, with 79 variants affecting protein sequence (Table S3 ). Of the total mutations, 54.4% were nonsynonymous single nucleotide variants (SNVs), followed by UTR (17.6%), synonymous (14.4%) and stopgain SNVs (7.2%), with the remainder being comprised of indels, splicing, and stoploss mutations.
Results and Discussion

F8 deficiency suppresses
The most common mutation events were A/T→G/C transitions (35.3%), while C/G→G/C transversions were the least represented (2.5%). This spectrum of mutations is consistent with previously published ENU experiments (33) . Variants exhibiting no recombination with the Tfpi locus on Chr2 (17 variants) were excluded from further analysis (See Methods). Sanger sequencing confirmation was performed for 62 variants, including all nonsynonymous and stopgain mutations. These variants were then checked for parent of origin (either the G1 mutagenized progeny or its non-mutagenized mate) as well as the original mutagenized G0 male.
Forty-seven of these variants were identified in the G1 mouse but not in the G0 or nonmutagenized parent, consistent with ENU-induced mutations. 
Actr2 as a candidate thrombosuppressor gene
The Actr2 gene encodes the ARP2 protein, which is an essential component of the Arp2/3 complex(35). ARP2, along with ARP3 and five other independent protein subunits (ARPC1-5),
forms the evolutionarily conserved seven-subunit Arp2/3 complex(36). Arp2/3 is a major component of the actin cytoskeleton and is found in most eukaryotic cells including platelets (37) .
Arp2/3 binds to the sides of actin filaments and initiates the growth of a new filament, leading to the creation of branched actin networks that are important for many cellular processes (38) . Loss of Arp2/3 function can have severe consequences, as illustrated by the embryonic lethality of mice homozygous for an ARP3 hypomorph (39) . In hemostasis, the Arp2/3 complex is necessary for actin-dependent platelet cytoskeletal remodelling events, which are essential for platelet activation and degranulation (40) (41) (42) . The Actr2 +/G mutation results in a p.R258G substitution in exon 7 of Actr2, at a highly conserved amino acid position, with arginine present at this position for all 60 available vertebrate sequences (https://genome.ucsc.edu), as well as in plants and fungi (Fig. 3B ). In addition, no variants at this position have been identified to date in over 120,000
human alleles (43) .
Actr2 hemizygosity is incompatible with survival
We attempted to generate an independent Actr2 knockin (Actr2 G ) allele by CRISPR/Cas9 genome editing. CRISPR/Cas9-induced homology directed repair (HDR)-mediated DNA integration within the Actr2 gene was tested in the Neuro-2a (N2a) cell line using two single guide RNAs (sgRNAs) and their respective single-stranded DNA (ssDNA) donor sequences for HDR-mediated knockin ( Fig. S2A and B, Table S5 ). In post-selected heterogenous N2a cells, we observed integration of the variant containing DNA sequence when using sgRNA #1 (Fig. S2C ).
We next injected 30 blastocysts and analyzed the 13 surviving to the 60-cell stage.
Genotyping of the 13 blastocysts produced from the sgRNA #1 injected oocytes exhibited a high degree of mosaicism, with all 13 positive for DNA cleavage events and 5 (38%) positive for The identification of novel factors involved in the regulation of hemostasis is challenging, as genes leading to marked shifts in hemostatic balance resulting in either severe bleeding or thrombosis are straightforward to identify clinically in humans, whereas subtle shifts are likely to escape detection given the multiple layers of buffering built into the complex hemostatic system (46) . The dominant sensitized suppressor screen reported here was undertaken to identify genes for which modest (<50%) reduction in function would significantly shift overall hemostatic balance. Such loci represent likely candidates for common human variation contributing to thrombosis and bleeding disorders. Gene variants with subtle yet significant antithrombotic effects represent attractive therapeutic targets because of a potentially wide therapeutic window with few unintended side effects. In contrast, a recessive screen would have been expected to identify known Mendelian bleeding disorders such as hemophilia A (F8 deficiency), as confirmed by the data in Figure 1A . Committee on the Use and Care of Animals (IACUC) approved all experiments using mice (protocol numbers PRO00007371, PRO00005191 and PRO00005913).
Genotyping
DNA was isolated from tail biopsies and mice were genotyped for Tfpi +/-and F5 L as previously described (14) . Mice were genotyped for F3 deficiency using custom primers listed in 
Genetic mapping
Genetic markers distinguishing the B6 and 129S1 strains distributed across the genome were genotyped using the Illumina GoldenGate Genotyping Universal-32 platform (Illumina, San Diego CA) at the University of Michigan DNA Sequencing Core. Linkage Analysis was performed on the Mendel platform version 14.0(50) using 806 informative markers from the total of 1449 genotyped markers. LOD scores >=3.3 were considered significant(51). Chrs 1 and 2 contained the F5 and Tfpi genes, respectively, and therefore these chromosomes were excluded from further analysis. The number of mice and the LOD scores for each of the mapped pedigrees are listed in Table S1 .
Sanger sequencing of the F3 gene and analysis of candidate mutations
Genomic DNA was extracted from mouse tail biopsies using the Gentra Puregene Tissue Kit (Qiagen, Germantown, MD). A total of 48 overlapping pairs of amplicons (primers:
F3gene_1-F3gene_35; upstreamF3_1-upstreamF3_13, Table S6 ) were used to Sanger sequence the entire F3 gene (~11kb) and an additional ~5kb of upstream sequences on both strands.
Sanger sequencing was performed at the University of Michigan Sequencing Core. For the analysis of candidate mutations, amplicons were generated harboring the nucleotide of interest using a custom outer primer pair. Inner forward and reverse primers were used to bidirectionally sequence these amplicons. Sequencing chromatograms were visualized and manually scored using FinchTV (PerkinElmer, Waltham, MA). identified by DNA genotyping) were tested for differential allelic expression. Three tissue samples (lung, liver, whole brain) were obtained from each mouse as previously described (22) .
Estimation of F3 allelic expression
RNA was extracted from the tissue samples using RNeasy Plus Mini Kit (Qiagen) according to manufacturer's recommendations and reverse transcribed using SuperScript II (Invitrogen, Carlsbad, CA). cDNA corresponding to exon 3-exon 5 was amplified with primers F3-exon-F and F3-exon-R using GoTaq Green Master Mix (Promega, Madison, WI). Primers F3-exon-F and F3-exon-R were also used to Sanger sequence the F3 exonic region.
Relative expression was estimated at SNP sites by dividing the area under the Sanger sequencing peak of one allele to another (52, 53) . Next, the relative expression of each SNP was compared between the B6 and 129S1 allele carrying progeny.
Mouse whole-exome sequencing
Libraries were prepared using Agilent (Agilent Technologies, Santa Clara, CA) or The Actr2-specific sgRNA sequences used in these experiments are listed in Table S5. sgRNAs were selected based on: 1) their proximity to the mutation site (< 100 bp away; 10 bp optimal); 2) the presence of a protospacer adjacent motif (PAM) "NGG" sequence adjacent to the sgRNA; 3) the ability to incorporate a synonymous variant within the PAM to protect the HDR donor template from Cas9-targeted degradation; and 4) the sequence must have an inverse likelihood of off-target binding score of >70 and no less than 3 mismatches within exonic regions of the genome as determined by the CRISPR design tool (crispr.mit.edu).
Single-Stranded DNA Donor for Homology Directed Repair:
The ssDNA oligonucleotides that served as HDR donor templates were ordered as Ultramer DNA oligos from IDT and are listed in Table S5 . The HDR donor template consists of a 161 bp genomic sequence homologous to a region spanning -44 to +117 bp from the splice junction of intron 6 and exon 7 of the mouse Actr2 gene (Fig. S2B ). The HDR donor encodes an arginine (R) to glycine (G) mutation at the yeast tRNA and 125 µg/ml Proteinase K) was added and the samples were incubated at 56°C for 10 min followed by 95°C for 10 min and immediately placed on ice to prevent heteroduplex formation. Crude lysates were stored at -20°C.
Multiplex PCR Genotyping:
We designed a two-reaction multiplex PCR strategy sensitive enough to detect wildtype (WT) and R258G alleles that differ by a single nucleotide. Common ACTR2_OF forward and ACTR2_OR reverse primers were used in separate reactions with the WT-specific reverse primer (ACTR2_WT-R) or the R258G-specific reverse primer (ACTR2_MUT-R) that only differ in the -1 position on the 3'-end (Table S6 ). Inclusion of the common primers (659 bp product) provided amplification competition and acted as a positive PCR reaction control. Amplification of the 318 bp product using ACTR2_WT-R or ACTR2_MUT-R allele-specific primers indicates the presence of the wildtype or mutant allele respectively (Figs. S2D and S3A).
SURVEYOR Nuclease Assay:
The genomic region flanking the CRISPR target site for Actr2 was PCR amplified using genomic primers ACTR2_OF and ACTR2_OR (Table S6) . Unpurified PCR products (30 µl) were subjected to a denaturing and reannealing process to enable heteroduplex formation: 95°C for 10 min; 95°C to 85°C ramping at -2°C/s; 85°C to 25°C at -0.3°C/s; 25°C for 1 min and 4°C hold. After reannealing, ~250 ng DNA products were treated with SURVEYOR nuclease and SURVEYOR enhancer S (IDT) following the manufacturer's recommended protocol for GoTaq DNA polymerase amplified products. Digested and undigested (Cut/Uncut) products were analyzed by standard gel electrophoresis using 2.0% TAE agarose gels containing ethidium bromide and were imaged with a Chemi-Doc Touch gel imaging system (Bio-Rad).
Statistical Data Analysis
Statistical differences among the potential progeny of mouse crosses were determined using the Fisher's Exact test. The student's t-test was used for estimating statistical differences between the weights of F5 L/L Tfpi +/-mice and their littermates. Relative expression differences for F3 alleles were estimated using the Wilcoxon rank-sum test. All the above statistical analyses were performed using the 'stats' package in R software. Kaplan-Meier survival curves with logrank test to estimate significant differences in mouse survival as well as significance for putative suppressors identified by exome sequencing were performed using the 'survival' package in Alternating red and black is used to highlight the chromosomes. Chrs 1 and 2 were excluded from further analysis since they contain the F5 and Tfpi genes, whose segregation was restricted by required genotypes at these loci. The Chr3 peak had the highest LOD score in the Chr3 subregion:117. Figure S1 : Relative expression analysis of F3 alleles. Expression differences between B6 and 129S1 alleles were estimated at three different SNPs: 1) rs30268372, 2) rs30269285, and 3) 30269288 using both forward (Fwd) and reverse (Rev) sequences of cDNA extracted from lung (red), liver (blue), and whole brain (green) tissues of adult mice. No significant differences were observed between the alleles in any of the tested tissues. Genotyping of heterogenous N2a cell populations post-puromycin selection. PCR was performed as described in Materials and Methods and depicted in Figure  S2C . (Wt and Mut indicates competitive PCR with primers ACTR_OF/R and WT-R or MUT-R, respectively; NTC=no template control). In post-selected heterogeneous N2a cells, the 318 bp band indicating the presence of the Actr2 G allele within the heterogenous cell population was observed when PCR was performed with the Mutant-specific primer (Mut) on gDNA isolated from cells co-transfected with sgRNA #1 + DONOR. Figure S3 : Actr2 hemizygosity is incompatible with survival. A. Actr2 R258G genotyping of three injected 60-cell stage mouse blastocysts and tail DNA from B6 control mouse. This is the same PCR scheme as Figure S2D . As expected, no mutant amplification is seen in B6 tail DNA sample. Amplification of the mutant allele is present in blastocysts #1 and #6 but not in #13. B. Surveyor assay for INDEL detection from products amplified with ACTR2_OF/R (C=cut; U=uncut). C. Sanger Sequencing chromatograms from the mouse blastocysts and B6 control. D. INDEL frequency for the three blastocysts determined by decomposition using TIDE software(64). Results indicate that all 3 blastocysts contain indels. Integration of the HDR donor template carrying the Actr2 mutation and synonymous PAM change within the blastocysts were detected by both PCR (Fig. S3A and B) and Sanger sequencing (Fig. S3D) . While integration of the HDR donor template is evident in blastocysts #1 and #6, they also contained multiple indels(64) (Fig. S3B-D) . Genetic mosaicism can occur with high frequency in founder mice derived using CRISPR/Cas9 genome editing(65). In our targeting strategy, the degree of observed mosaicism was likely due to persistent Cas9 expression. 
129S1 Background
F5 L/+ Tfpi +/-x F5 L/L B6 Background F5 L/+ x F5 L/+ F5 Genotype L/+ L/+ L/L L/L +/+ L/
17.1% (86)
A ~50% reduction of live weaning age F5 L/L mice >N12 on the 129S1 background is observed compared to F5 L/L mice >N12 on the B6 background (shown in bold). tcatcgagcctctagccttt  CUX1_OF  gaccctttgatcaggagctg  CUX1_OR  ggcttgcctagaattcacca  CUX1_IF  ggcgacacatcagtctttga  CUX1_IR  gtgcagcgtctacacgacat  CCR1_OF  ggaatgccccattttgttta  CCR1_OR  tgctatgcagggatcatcag  CCR1_IF  gaccttccttggttgacacc  CCR1_IR  ctgctcagaagacccagtga  RIC8B_OF  gaacagaagaaccgggactg  RIC8B_OR  gcctgggagctactctcaaa  RIC8B_IF  ccctgaatggaatggagaga  RIC8B_IR  acaaatgcccaagtctgacc  GRIA1_OF  gaaggccaactgattttcca  GRIA1_OR  tggcatcacattttcatggt  GRIA1_IF  agctgatttgctggactggt  GRIA1_IR  gtcccacgtttgacttggat  DHX8_OF  cagtgctctcgttgtgcttt  DHX8_OR  cttcccttgccaccacag  DHX8_IF  acccagacagacccactcac  DHX8_IR  ccatggaacactgtctctgc  ANKRD55_OF  ccacctttgacagtgtcgtg DLGAP1_IF   ccaaacgcttccattgttct  DLGAP1_IR  caaagagcccttcctctcct  TMPRSS11E_OF  tgaaagcctgcatgaaagaa  TMPRSS11E_OR  agacgagacagtgggtctgg  TMPRSS11E_IF  tcagcaaataaagggcaaga  TMPRSS11E_IR  tgtgctcgacagtgtctgct  TMEM52B_OF  ggatatcacctttgggtgtga  TMEM52B_OR  tgcatgctgtagttgaaggaa  TMEM52B_IF  ctcatgcacacagctccttg  TMEM52B_IR  ccttaatgttccatgctttgg  TMTC_OF  tatctgctgccaaagcactg  TMTC_OR  tgccattgaaccttatgctg  TMTC_IF  cagtgtgctctcctctgctg  TMTC_IR  gattccttaggggagccttg  AP2A2_OF  gagtggcctactggctgttc  AP2A2_OR  tgcacaagtggaacttggag  AP2A2_IF  atggtcttgccaaggcttta  AP2A2_IR  ctcatctgtcccatgtgctg  ACTR2_OF  ataaatgcaggctcccacaa  ACTR2_OR  ccggttggttggtttttaag  ACTR2_IF  ctgtggcctatccgtgtctt  ACTR2_IR  agcttttgggggtcagtttt  ACTR2_MUT-R  atcattaaggrrggaggagaag  ACTR2_WT-R  atcattaaggttggaggagaac  USP43_OF  catgtcacctcgaaacaaagg  USP43_OR  tgcttaaccgcttcctgcta  USP43_IF  tggttcacacgcttttcaag  USP43_IR  ctacgatggcgatggagaag  LYZ2_OF  agcatccctcttgagcatcc  LYZ2_OR  cagaggtgtctgtgtggtga  LYZ2_IF  aggcagagcatcaaactgcc  LYZ2_IR agggctgtgctgactgaca
